- Home
- NDLS vs LSTA Comparison
NDLS vs LSTA Comparison
Compare NDLS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | LSTA |
|---|---|---|
| Founded | 1995 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 28.9M |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NDLS | LSTA |
|---|---|---|
| Price | $11.69 | $3.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 52.0K | ★ 95.7K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.37 | ★ 56.90 |
| 52 Week Low | $0.47 | $1.81 |
| 52 Week High | $12.11 | $5.07 |
Technical Indicators
Market Signals| Indicator | NDLS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 78.29 | 28.58 |
| Support Level | $0.62 | $1.91 |
| Resistance Level | N/A | $4.95 |
| Average True Range (ATR) | 0.69 | 0.31 |
| MACD | 0.20 | -0.11 |
| Stochastic Oscillator | 92.42 | 19.03 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.